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Abstract
Autoimmune gastritis (AIG) is a chronic inflammatory disease of the gastric 
corpus and fundus. Although still unclear, genetic and environmental factors, 
antigenic mimicry or cross-reactivity are proposed pathogenic mechanisms. 
Parietal cells destruction results in loss of intrinsic factor and increased gastric pH 
due to hypochlorhydria and G-cell proliferation. Furthermore, atrophy, intestinal, 
pancreatic and spasmolytic polypeptide-expressing metaplasia are observed. AIG 
is underdiagnosed, however, proper diagnostic approach, including endoscopic, 
serological and histopathological assessment, is required. Gastroscopy with corpus 
and fundus biopsies is a gold standard. A serological combination of anti-parietal 
cell antibodies, intrinsic factor antibody, anti-Helicobacter pylori IgG, gastrin, pep-
sinogen I and pepsinogen I/II ratio improves the diagnostic sensitivity and specific-
ity and allows atrophy level prediction. AIG might manifest with multifactorial 
iron deficiency anemia, vitamin B12 deficiency (pernicious anemia), neurological 
and neuropsychiatric conditions, small intestinal bacterial overgrowth and gas-
trointestinal infections. AIG association with other autoimmune diseases is well-
established. Gastric cancer and gastric carcinoid are neoplastic transformations of a 
continuous chronic inflammation. Patients with AIG should be carefully monitored 
as no specific AIG therapy is available and disease complication could be fatal.
Keywords: autoimmune gastritis, parietal cells, atrophy, metaplasia, pernicious 
anemia
1. Introduction
First reported by Thomas Addison (1849) as an atrophic gastritis with auto-
immune etiology and co-existing distinctive type of anemia, the autoimmune 
gastritis (AIG) represents a chronic gastric inflammation with progression to 
mucosal atrophy, occurring in up to 8% of the general population. Since parietal 
cells antibodies (PCA) and anti-intrinsic factor antibodies (AIFA) have been first 
reported by Schwartz (1960) and Irvine (1962), the autoimmune conception of this 
type of gastritis is recognized. The autoimmune reaction with CD4+ T cells leads 
to destruction of parietal cells, which are unique cells in the corpus and fundus 
glands. Therefore, AIG is located in stomach corpus and fundus, which distinguish 
AIG from other diseases, leading to gastric atrophy (H. pylori infection, drugs etc.). 
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Based on Sydney System, pyloric or intestinal glands replace the oxyntic glands. The 
consequences of the loss of parietal cells are hypochlorhydria, gastric pH increase-
ment and decreased production of intrinsic factor with concomitant megaloblastic 
pernicious anemia in the end-stage due to vitamin B12 malabsorption. Patients 
might suffer from iron deficiency anemia due to hypochlorhydria and inadequate 
iron uptake. Gastrointestinal symptoms are rarely reported. AIG is often presented 
with other autoimmune co-morbidities (thyroid autoimmune disease, type 1 dia-
betes, etc.). Although gastrointestinal symptoms are rarely reported, a malignant 
transformations, namely intestinal-type gastric cancer and type I gastric carcinoid 
are observed in respectively 5.3% and ca. 9% of AIG patients [1–3].
2. Epidemiology
Nowadays the prevalence of AIG is difficult to obtain, as the disease occurs asymp-
tomatic in early stages, remains undiagnosed for a long period as symptoms arise with 
atrophy and mucosal dysplasia progression. Further explanations for the underdiag-
nosed AIG are the inadequate and not from the right location biopsy sampling and the 
poor identification of the etiology of anemia, which is one of the AIG manifestations. 
Estimated incidence is ca. 2% in younger and up to 12% in elderly patients. Studies 
demonstrate increased prevalence of AIG with advancing age and in patients with H. 
pylori infection (Zhang et al.). Females are more often affected than males (3:1 ratio), 
although this has not been consistently observed. Cabreta et al. in their randomized 
study find no age difference. The reported prevalence of pernicious anemia, which 
is one of the most typical AIG manifestations, is about 0.1% in the general popula-
tion and about 2% in elderly (older than 60 years). The prevalence of pernicious 
anemia does not differ between populations (white, African American and non-white 
Hispanic). A study of Carmel and Johnson elucidate that African American women 
develop pernicious anemia at significantly younger age. Association with other auto-
immune diseases (autoimmune thyroid diseases - Hashimoto’s thyroiditis and Graves’ 
disease, type 1 diabetes, vitiligo, Addison’s disease etc.) is documented to addition-
ally increase the prevalence to up to 35%. This consequence determines a multiple 
autoimmune diseases (MAS) type 3B and 4. Pernicious anemia is present in patients 
with Graves’ disease, Hashimoto’s thyroiditis, type 1 diabetes, autoimmune thyroid 
disease, Addison’s disease, primary hypoparathyroidism and vitiligo in 2, 4–12%, up 
to 4, 2–12, 6, 9 and 3–8%, respectively. Recent data direct the attention to the possible 
association between H. pylori infection and AIG development in respect to molecular 
mimicry between H. pylori antigens and the gastric H+/K+ adenosine-triphosphate 
enzyme (ATPase). Few studies evaluate the incidence of AIG (using histology, PCA 
positive levels) in patients with iron deficiency anemia (IDA) of unknown etiology. 
The estimated prevalence varies between 15 and 27%. The profile of patients with 
IDA and positive PCA are younger females with lower hemoglobin and ferritin levels 
and who suffer more often from restless legs syndrome [1, 2, 4–14].
3. Pathogenesis
AIG is a chronic inflammation, localized in the gastric corpus and fundus. 
The inflammatory processes start with lymphocytes and plasma cells infiltra-
tion in lamina propria with involvement of deep layers, leading to parietal cells 
destruction. Because of preservation of relatively normal oxyntic mucosa, a gastric 
pseudopolyposis appears (also known as “islands in the sea”). The loss of parietal 
cells results in hypochlorhydria and further in G-cell hyperplasia due to missing 
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negative feedback, leading to higher gastrin secretion in the antrum. A further 
consequence of the increased gastric pH is the parietal cell pseudohypertrophy. The 
higher gastrin secretion leads to direct stimulation of enterochromaffin-like (ECL) 
cells and their proliferation in hyperplastic, dysplastic and neoplastic subtypes that 
might onset a carcinoid tumor. Pseudopyloric metaplasia (“oxyntic antralization”, 
spasmolytic polypeptide-expressing metaplasia (SPEM)), intestinal metaplasia 
(IM) and pancreatic metaplasia can be observed. SPEM can be transformed into 
IM, which represents the replacement of gastric mucosa with intestinal epithelium 
(small intestinal and colonic). AIG results in microcytic iron deficiency anemia and 
megalocytic pernicious anemia due to vitamin B12 deficiency [2, 4].
3.1 Immunogenetic factors
AIG and PCA are observed in 20–30% of the family members of patients with 
pernicious anemia. However, a genetic predisposition has been proposed. Although 
the association between pernicious anemia and particular HLA haplo/genotypes is 
weak, studies evaluate HLA DR4, with DR2 and DR5 haplotypes. A genetic het-
erogeneity is observed in respect to DR3/DR4 genotype, which is found in patients 
with pernicious anemia and concomitant endocrinopathy. Using murine models, 4 
distinct genetic regions of susceptibility genes for AIG were identified (Gasa1, 2, 3 
and 4) on chromosomes 4 and 6 and H2 region. Interestingly, three of these genes 
are nonmajor histocompatibility complex genes and are located on the same locus 
with those of type 1 diabetes, which could explain the strong concordance between 
AIG and type 1 diabetes [2, 15–18].
3.2 Cell-mediated autoimmunity
Cell-mediated autoimmunity has a key role for the AIG development. The main 
trigger of autoimmunity are the 100-kd catalytic α-subunit and the 60- to 90-kd 
glycoprotein β-subunit of the gastric H+/K + -ATPase, which membrane protein is a 
proton pump. PCA and AIFA are found in both serum and gastric juice. The higher 
the PCA titer is, the more severe the corpus atrophy is and the lower the parietal cells 
concentration is. The loss of parietal cells is a consequence of mainly CD4+ CD25− 
Th1 resting lymphocyte effectors initiated perforin-mediated cytotoxicity (perforin/
granzyme B pathway) or Fas–FasL apoptosis. CD4+ CD25− Th1 resting lymphocyte 
effectors produce IFN-γ and TNF-α. Submucosa, lamina propria and gastric glands are 
infiltrated by CD4 + CD25− T-cells, together with macrophages and B lymphocytes, 
leading to loss of parietal (CD4+ T cells react to H+/K+-ATPase α chain and marginally 
to the β chain), principal and P/D1 ghrelin-producing cells [2, 5, 15, 19–21].
3.3 Humoral autoimmunity
Two types of antibodies are produced by B cells from activated CD4+ T cells in 
patients with AIG, namely PCA (antibody to the parietal cells) and AIFA (antibody 
to the produced by the parietal cells a 60-kDa glycoprotein intrinsic factor). PCA 
are found in the serum and gastric juice in up to 90% and AIFA in 30–50% of AIG 
patients. Α catalytic and β subunits of gastric H+/K + -ATPase are bound by PCA. In 
end-stages of AIG the PCA titer decreases because of parietal cells loss. Researchers 
have found two types of AIFA from IgG class. Type 1 is present in 70% of patients 
and acts as a blocking antibody that reacts with the binding site for vitamin B12. 
Type 2 AIFA is present in 30% of patients and is a precipitating antibody that binds 
other binding sites from vitamin B12 and impedes binding of intrinsic factor-
vitamin B12 to the receptors in the ileal mucosa [5, 22–24].
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3.4 Association with H. pylori
H. pylori, which is well-established etiological factor for atrophic gastritis 
development, may induce AIG through mechanisms of molecular mimicry at the 
T-cell level (autoreactive T cells against gastric proton pump), bystander activation 
and / or epitope spreading. This hypothesis is supported by recent studies as some 
patients may have AIG with co-existing H. pylori infection (20–50%). H. pylori 
leads to development of various antibodies, including PCA and anticanalicular 
antibodies against the H+/K+ ATPase, which are in fact most frequent. Studies 
show a high homology between the β subunit of H. pylori urease and the subunit β 
of gastric proton pump, which is a precondition for cross-reactivity against parietal 
cells and IFN-γ production, resulting in killing or apoptotic suicide. Some patients 
with PCA and/or AIFA, who underwent H. pylori eradication, demonstrated loss 
of antigastric antibodies. However, the correlation between AIG and H. pylori still 
remains controversial. AIG patients with observed gastric atrophy or IM in the 
course of H. pylori infection do not decrease their risk for gastric cancer develop-
ment even after H. pylori eradication [2, 5, 25–30].
3.5 Endocrine factors
AIG is frequently associated with other autoimmune diseases. Emphasized is the 
link to type 1 diabetes and autoimmune thyroid disease (Hashimoto’s thyroiditis and 
Graves’ disease). Reported risk factors for patients with AIG and type 1 diabetes are 
persistent positive islet cell antibody and positive glutamic acid decarboxylase-65 
antibody, which is found in the thyroid gland and stomach except in pancreas and 
brain. Studies demonstrate that type 1 diabetes itself and not hereditary might be 
a risk factor for AIG development. Positive thyroid peroxidase autoantibody are 
reported in up to 50%of AIG patients due to possible cross-reaction. As PCA are 
verified in up to 40% of patients with autoimmune thyroid diseases, screening the 
patients of this population for AIG should be recommended. Other reported co-
existing autoimmune conditions are polyglandular autoimmune syndromes (mainly 
type 3B), Addison’s disease, vitiligo, perioral cutaneous autoimmune diseases 
(mainly erosive oral lichen) and myasthenia gravis [2, 4, 7, 31–34].
4. Diagnostic approach
4.1 Serological tests
The evaluation of AIG-associated autoantibodies (PCA and AIFA), anti-H. 
pylori antibodies (anti-HP-IgG) and markers for gastric atrophy (gastrin and 
pepsinogen levels) is used for serological noninvasive diagnosis of AIG (“serologi-
cal biopsy”, the so-called GastroPanel test (ELISA test, Biohit, Helsinki, Finland)). 
AIG-associated autoantibodies are widely used for screening and diagnosis of 
AIG. They differ according to their sensitivity and specificity as PCA is higher sen-
sitive (80% compared to 50% sensitivity for AIFA) but less specific for pernicious 
anemia detection. Studies are controversial whether PCA levels correlate with AIG 
severity or not. Due to low gastric acid output and G-cells stimulation and elevated 
gastrin secretion in patients with atrophic autoimmune gastritis, it is crucial to 
evaluate gastrin levels (usually gastrin 17) as gastrin correlates strong with gastric 
atrophy based on histopathology. Other useful atrophy markers are the produced by 
the chief cells of oxyntic mucosa of stomach corpus and fundus pepsinogen I and 
the secreted by the chief cells and mucous neck cells of the whole stomach mucosa 
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pepsinogen II. In patients with atrophic autoimmune gastritis are demonstrated 
significant decrease of pepsinogen I (low pepsinogen II levels are not commonly 
observed) and low Pepsinogen I/Pepsinogen II ratio (<3). In respect to diagnosis of 
pernicious anemia, a panel of vitamin B12, homocysteine and methylmalonic acid 
measurement is required. In those patients may be observed thrombocytopenia, 
increased levels of LDH and bilirubin, and rarely schistocytes in the peripheral 
smear. Iron deficiency anemia, which is often present in patients with AIG, should 
be identified by levels of hemoglobin, mean corpuscular volume (MCV), serum 
iron, ferritin, total iron-binding capacity (TIBS) and serum transferrin receptor 
(TfR). In patients with suspected carcinoid tumor transformation the measurement 
of chromogranin A, which is secreted by the ECL cells, can be useful, although it 
shows low specificity (23%) and false-positive results in patients with inflamma-
tory bowel disease, renal insufficiency and other conditions [4, 23, 35–45].
4.2 Endoscopy
Of a great importance for AIG diagnosis is the performance of gastroscopy 
with separately collected biopsies - two from the corpus, two from the antrum and 
one from the incisura angularis (updated Sydney System recommendations). New 
endoscopic techniques (magnifying endoscopy, autofluorescence and narrow-band 
imaging) improve the diagnostic accuracy as they provide information for minimal 
gastric atrophic changes. A number of endoscopic appearances can be present: 
polyps (hyperplastic or adenomatous), pseudopolyps, flattened rugal folds, visible 
submucosal vessels, loss of subepithelial capillary network resembling honeycomb, 
collecting venules in regular shape and appearance and vascular pattern and 
swelling of areae gastricae. A combination of them improves the sensitivity and 
specificity of the procedure. In early AIG stages with minimal or no endoscopi-
cal and histological changes, gastric acid production is increased due to hypo- or 
achlorhydria. Thus, gastric acid measurement (simple intragastric pH measurement 
or volume of acid secretion) might be useful for early AIG diagnosis [1, 4, 46–52].
4.3 Histopathology
Histopathological assessment of biopsies form gastric corpus and fundus 
remains gold standard for AIG diagnosis even in early stages of the disease. 
The correct site of biopsy is of great importance for the proper AIG diagnosis, 
which could be tested by immunohistochemical staining of G cells (gastrin). 
Histological characteristics change with disease progression. Typical but non-
specific for AIG are lymphoplasmacytic infiltration in lamina propria, which is 
mainly multifocal with accentuation in the deeper; glandular portion in early 
stage and diffuse lymphoplasmacytic infiltration of the lamina propria in end-
stage; focal to profound atrophy of oxyntic mucosa with disease progression. 
End-stage AIG is further characterized by distinct reduction or total loss of oxyn-
tic glands with pseudohypertrophy of parietal cells due to fragmentary oxyntic 
glands destruction in end-stage of AIG; SPEM presence; pancreatic or intestinal 
metaplasia; ECL cells hyperplasia with additional samples immunohistochemical 
testing with chromogranin A and synaptophysin [1, 4, 11, 53–57].
5. Clinical presentation
Symptoms vary during the course of AIG as patients at early stages are most 
often asymptomatic, which makes the diagnostic approach only on clinical 
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presentation challenging. With disease progression a wide spectrum of gastrointes-
tinal, hematological and neurological signs and symptoms arises [1, 3, 4].
5.1 Gastrointestinal manifestations
Gastrointestinal symptoms are not the leading presentation of patients with 
AIG. Carabotti et al. report in their recent study frequency of one or more gas-
trointestinal symptoms in 56.7% of AIG patients. Female gender, younger age 
(<55 years) and non-smoking are independent risk factors for gastrointestinal 
symptoms manifestation. More than half of the patients had upper gastrointestinal 
complains as most frequent one was vague dyspepsia in respect to post-prandial 
fullness and/or early satiation. Furthermore, as achlorhydria is a major patho-
genetic consequence of AIG, patients may suffer from bloating, delayed gastric 
emptying, small intestinal bacterial overgrowth, and gastrointestinal infections 
such as Clostridium difficile. Pain and peptic or duodenic ulcers are not reported. 
Atrophic glossitis due to vitamin B12 deficiency is an early stage AIG manifestation. 
Interestingly, heartburn (24%) and acid regurgitation (12%) are presented in a 
study of Miceli et al., which could develop from nonacidic refluxes. Data exist to 
support the observation that gastroesophageal reflux disease and its complications 
like Barrett’s esophagus may develop even in AIG patients [1–4, 6, 58–69].
5.2 Hematological manifestations
Typical hematological manifestations of AIG are iron deficiency anemia (IDA) 
in the early stages and pernicious anemia in the end-stage of the disease.
IDA is the leading hematological manifestation, occurring in 50% of AIG 
patients as reported by Hershko et al. Several epidemiological studies demon-
strate IDA in younger patients prior to pernicious anemia development. Iron 
metabolism, which is regulated by an uptake, is impaired in AIG mainly due to 
the presence of achlorhydria. Different mechanisms of IDA with AIG etiology are 
observed. For the necessary reduction of the ferric form of inorganic iron (the 
iron type in food) to ferrous as well as for releasing the ferric/ferrous iron from 
its protein-complex in order to precede to an iron uptake, gastric acid is needed. 
Another cause for IDA in AIG is the decreased iron absorption due to lack of 
ascorbic acid, destroyed in AIG. IDA symptoms vary as the commonly reported 
are fatigue, brittle nails, hair loss, restless legs syndrome, immune dysfunction, 
ineffective wound healing, while due to anemia itself tachycardia, shortness of 
breath, dizziness, lightheadedness and cognitive and physical dysfunction may 
develop. Pregnant women are at risk of early birth and underweight newborns. 
Of great importance is that IDA with AIG etiology is refractory to iron therapy 
[1, 4, 6, 13, 20, 58–60, 70–75].
Pernicious anemia is usually caused by vitamin B12 deficiency due to loss 
of intrinsic factor and insufficient releasing of vitamin B12 from the food due 
to low levels of gastric acid. Vitamin B12 is a key regulator of DNA synthesis. 
Mostly affected are patients at advanced age due to age-related reduced absorp-
tion and minimal turnover with further large stores of vitamin B12. The clinical 
manifestations vary widely; therefore pernicious anemia is so-called “great 
pretender”. Reported symptoms of pernicious anemia are fatigue, lightheaded-
ness, palpitations, angina pectoris and congestive heart failure and mental 
disturbances. Patients are at increased risk of endovascular dysfunction and 
myocardial infarction and pulmonary embolism due to hyperhomocysteinemia 
and the related thrombosis. Therefore, untreated pernicious anemia may lead to 
lethal exit [1, 4, 6, 20, 58–61, 76–80].
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5.3 Neurological manifestations
Neuronal death due to demyelination and axonal damage leads to the typi-
cal neurological manifestation of vitamin B12, which might be present even in 
patients with no hematological changes. The loss of vibratory and position sensa-
tions together with distal paresthesias develop from damages in the lateral and 
posterior columns of the cervical and upper thoracic segments of the spinal cord. 
This syndrome is called a subacute combined degeneration and is very specific 
for pernicious anemia. Other vitamin B12 deficiency presentations are peripheral 
neuropathy (paresthesia and numbness of the lower extremities), optic neuropathy 
and neuropsychiatric conditions (dementia, mania, depression, psychosis, obses-
sive–compulsive disorder, etc.). Proper diagnosis and early vitamin B12 substitution 
are mandatory to delay progression and for better outcome [1, 4, 81–89].
6. Neoplastic transformations
Patients with AIG are at increased risk of gastric cancer development. The 
estimated prevalence is about 5.3% as recent studies suggest even higher incidence 
- 14.2 per 1000 person-years with patients with AIG having risk of gastric cancer 
development 3 to 6-fold higher than the general population. Recent meta-analysis 
demonstrates 0.27% per person-year with an overall relative risk of 6.8 (95% CI 
2.6–18.1) for gastric cancer development. Elderly people, chronic inflammation due 
to H. pylori infection, achlorhydria, presence of dysplasia and intestinal metaplasia 
are significantly risk factors for gastric tumorogenesis [1, 57, 90].
6.1 Gastric carcinoid
Gastric carcinoids are verified in 4–9% of patients with AIG and pernicious 
anemia. 50–85% of all gastric carcinoids develop in patients with AIG. Three types 
of gastric carcinoids are established, of which type I is found in patients with 
AIG, type II is associated with Zollinger-Ellison syndrome and multiple endocrine 
neoplasia I and type III carcinoid is the most aggressive type. Achlorhydria is a 
key factor for the development of gastric carcinoids in AIG patients. As described, 
achlorhydria leads to loss of negative feedback and G-cells stimulation in antrum, 
followed by hypergastrinemia (typical for type I and II carcinoids). The high 
gastrin levels demonstrate trophic effects on ECL cells hyperplasia, which further 
may result in dysplasia and transformation into gastric carcinoid. Gastric carcinoids 
are quite benign lesions with low metastatic potential (less than 10%). Patients 
with gastric carcinoids are usually asymptomatic. However, they may complain of 
dyspepsia, abdominal pain, flushing, diarrhea and symptoms of anemia. Classical 
carcinoid syndrome is seen very rare. Carcinoids are usually diagnosed incidentally 
during endoscopy in patients with anemia. Gastroscopy with biopsy sampling with 
further immunostaining for chromogranin A and/or neuron-specific enolase is the 
best diagnostic approach. The presence of polyps in the stomach body in patients 
with AIG is significantly associated with type I carcinoid. As long as polyps might 
be underdiagnosed during endoscopy, serum chromogranin A levels are more 
accurate for carcinoids diagnosis. Chromogranin A levels correlate strong with 
gastrin levels and ECL cell density in the corpus and fundus mucosa, represent-
ing high specificity (59%) and sensitivity (100%). According to the algorithm of 
Gilligan et al. based on size and number, gastric carcinoids in AIG patients, which 
size is <1 cm and the number is 3–5, should be removed endoscopically, and those 
>1 cm and/or > 5 should be followed by antrectomy. Surveillance at every 6-month 
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is proposed. Another therapeutic option is the administration of octreotide, which 
leads to lower gastrin levels, improved ECL status and even spontaneous regression 
(Ferraro et al.) [1, 2, 4, 45, 90–110].
6.2 Gastric cancer
The chronic inflammation, which is an integral part of the pathogenesis of AIG, 
increases significantly the risk of malignant transformations. Achlorhydria, high 
dietary salt intake and bacterial overgrowth are proposed risk factors. Furthermore, 
the concomitant H. pylori infection additionally increases the risk of precancerous 
lesions. Current studies suggest that cancer stem cells, which might be exposed on 
mutations, have an important role in cancerogenesis. This concept is assumed as 
stem cells are well-known for their longevity and inherent capacity for self-renewal. 
As a consequence of chronic inflammation, stem cells level and proliferation 
potential increase, which favors their intestinal metaplasia (possible phenotype of 
stem cells abnormality) and dysplasia. In 1988, Correa and Piazuelo proposed the 
so-called “Correa hypothesis/cascade” for gastric cancer development in patients 
with H. pylori infection: unknown genetic and epigenetic factors lead stepwise to 1. 
chronic inflammation; 2. atrophy gastritis; 3. intestinal metaplasia; 4. low to high 
grade dysplasia, which finally results in gastric cancer in some patients. H. pylori 
factors, associated with higher malignancy potential are CagA-positive strains, 
VacA gene and s1 m1 [1, 4, 5, 111–120].
An attention is paid at the role of tumor-associated autoantigens in immuno-
genicity and immunodiagnosis, which may detect cancer at early stage. Usually 
these autoantigens are cellular proteins, which can be ectopically expressed or a 
result from genetic mutations and rearrangements. Additional mutations in the 
tumor-associated autoantigens lead to new antigenic epitopes and finally increased 
immunogenicity. According to a current concept of the immunological response 
of cancer tissue, tumor-associated antigens lead to autoantibodies production. 
Autoantibodies with potential clinical usefulness are anti-carcinoembryonic 
antigen (CEA), anti-p53, anti-survivin, anti-mucin, and anti-livin autoantibodies. 
The autoantibodies are missing in healthy people and non-cancer diseases. Thus, 
autoantibodies against tumor antigens can serve as biomarkers and may have the 
potential to verify an early stage cancer, which may significantly improve patients 
diagnosis and outcome as the majority of patients with gastric cancer are diagnosed 
late, when are symptomatic and the management is rather palliative. Studies show 
significant lower levels of biomarkers after radical tumor resection, which suggest 
their prominent role in patient monitoring [5, 121–125].
The estimated frequency of detection of anti-carcinoembryonic antigen (CEA) 
anti-survivin, anti-mucin, and anti-livin autoantibodies is 46–56, 40, 75 and 50%, 
respectively, as anti-CEA is found in 10% of healthy people. They are present in the 
early stage of gastric cancer and demonstrate a good prognostic value for survival 
and postoperative monitoring, especially in patients without anti-p53 antibodies 
[123, 126–131].
p53 is a key factor in carcinogenesis. In 46% of patients with p53-positive 
gastric cancer are found increased anti-p53 antibodies levels. Anti-p53 antibod-
ies, which are first reported in patients with breast cancer, correlate significantly 
with the tumor suppressor gene p53 protein expression, demonstrating about 
96% specificity for neoplastic detection. In contrast to anti-carcinoembryonic 
antigen (CEA) anti-survivin, anti-mucin, and anti-livin autoantibodies, anti-p53 
antibodies are not appropriate markers for early diagnosis and prognosis as they 
are detected in advanced gastric tumors with regional lymph node involvement 
[123, 126, 132–134].
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Extracellular protein kinase A (ECPKA) is a cAMP-dependent intracellular 
enzyme. Anti- ECPKA antibodies are significantly increased in patients with gastric 
cancer and other malignancies. They have the potential to be future universal 
screening method for tumors of different origin as their sensitivity and specificity 
are very high - 90 and 87%, respectively [135].
The presence of substantial number heterogeneous autoantibodies varies widely 
and demonstrates high specificity but low diagnostic sensitivity. To improve their 
sensitivity in order to enable their application in clinical practice for screening and 
diagnosis of gastric cancer; it is reasonable to promote a combination of serological 
AIG- and tumor biomarkers, microRNAs and/or glycosylation signatures. Using a 
combination of 5 biomarkers (MAGEA4, CTAG1, TP53, ERBB2_C, and SDCCAG8), 
Werner et al. demonstrated 32% sensitivity and 87% specificity for diagnosis of 
early stage gastric adenocarcinoma. In a study of Zhou et al. a combination of 7 
markers, namely p53, Koc, p62, c-myc, IMP1, survivin and p16, identified gastric 
cancer with sensitivity and specificity of 64% and 87%, respectively. Wang et al. 
verified a panel of 8 biomarkers (IMP1, p62, Koc, p53, c-myc, cyclin B1, survivin 
and p16), able to detect gastric cancer with 56.1% sensitivity and 86.2% specificity 
[136–144].
7. Treatment
Up-to-date there is no consensus on whom to screen for AIG and how often. 
The treatment management of AIG with avoiding further complications requires 
according to the present symptoms, serological results and imaging data proper 
follow-up. A proper monitoring with testing once a year complete blood count, 
gastrin, iron and vitamin B12 levels seems to be beneficial. Therapy depends on 
the stage of AIG, H. pylori infection, current nutrient deficiencies, concomitant 
autoimmune conditions and (pre)malignant transformation. As described above, 
H. pylori infection may play a crucial role in AIG pathogenesis. However, screening 
for H. pylori (serological anti-HP-Ig G and Ig M, fecal HP-antigen, breath tests, 
histological and cultural methods) in patients with AIG, gastric atrophy, intestinal 
metaplasia/dysplasia, and hypo- or achlorhydria should be performed. If positive 
for H. pylori, patients need subsequent treatment and eradication. Studies support 
H. pylori treatment as H. pylori eradication was associated with decreased levels of 
PCA and AIFA and AIG early stages healing. Oral supplementation with vitamin 
B12, iron and folic acid is recommended in early stages of AIG. With neurologi-
cal symptoms occurring, parenteral vitamin B12 should be applied. As long as 
various autoimmune diseases are recognized as AIG co-morbidities, attention 
should be paid at their screening and following treatment. Researchers recom-
mend the routine screening for type 1 diabetes and autoimmune thyroid diseases. 
On the other hand, in patients, who are diagnosed with type 1 diabetic (positive 
glutamate decarboxylase-65 antibodies) and autoimmune thyroiditis (positive 
thyroid peroxidase antibodies), PCA should be investigated at the disease’s onset 
and thereafter yearly for 3 years and later on a longer intervals if there is no AIG 
clinical signs. Screening for AIG in those patients’ populations might avoid the 
development of IDA and pernicious anemia with their above mentioned serious 
complications. As long as gastric carcinoid is curative, proper diagnosis and radical 
treatment are essential. According to size, number and location of gastric cancer /
carcinoid, polypectomy, antrectomy (gastrin-producing part), surgical eradica-
tion of a gastric tumor, with resection of adjacent lymph nodes or medicamentous 
treatment with further surveillance is performed. Somatostatin analogs are used as 
they can reduce gastrin and chromogranin A levels in patients with neuroendocrine 
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tumor (carcinoid). Promising therapeutic option is the gastrin receptor antagonist 
Netazepide, leading to decreased chromogranin A levels together with cancer 
size and number. A new technique for carcinoid tumors treatment is the peptide 
receptor radiotherapy, which would be worth to be tested in AIG patients. Whether 
to perform surveillance program with regular endoscopic and histological examina-
tion in patients with AIG or not remains controversial and guidelines according to 
AIG surveillance are missing. If mild to moderate dysplasia or ECL cell hyperplasia 
are observed, an endoscopic surveillance every 5 years is proposed. In contrast to 
the rare and with far better prognosis carcinoids, gastric cancer development might 
be fatal. According to the American Society for Gastrointestinal Endoscopy recom-
mendations (2006) for monitoring of patients with H. pylori atrophic gastritis, 
depending on the primary endoscopic finding the follow-up should be in intervals 
of 3–5 years (patients with simple, linear/micronodular hyperplasia); every 3 years 
(patients with extensive atrophy/IM) or every year (patients with adenomas/low-
grade dysplasia) [1, 2, 11, 90, 103, 109, 113, 145–153].
8. Discussion
Although H. pylori is a leading cause for gastritis, AIG frequency is increasing in 
elderly people and in those with other autoimmune pathology. As AIG is commonly 
underdiagnosed, AIG should be considered in the differential diagnosis of patients 
with anemia, dyspepsia and especially in those with concomitant autoimmune 
thyroid disease and type 1 diabetes and with relatives with gastric neoplasia. H. 
pylori presence does not exclude AIG in the pathogenesis of an underlying gastri-
tis. Screening of patients with a panel of serological markers pepsinogen I and II, 
gastrin, and/or H. pylori antibodies as well as the antibodies PCA and AIFA directs to 
the need of gastroscopy. However, gastroscopy with separately collected biopsies and 
histopathological assessment of specimens form gastric corpus and fundus remain 
the gold standard for AIG diagnosis. Asymptomatic in the early stages of the dis-
ease, AIG is not recognized in guidelines as an etiological factor for iron deficiency. 
However, AIG is often leading to iron deficiency anemia, which requires a different 
treatment strategy. Untreated pernicious anemia, which is a later manifestation of 
AIG, could cause both neurological complications and letal cardiovascular events. 
AIG is a precancerosis for the development of gastric cancer and neuroendocrine 
tumors. An effort is required to identify a biomarker panel with high sensitivity for 
early-stage gastric malignancy diagnosis. The treatment of AIG still remains chal-
lenging due to asymptomatic early stage and complex pathogenesis of the disease.
9. Conclusion
Proper and early diagnostic approach and prevention, followed by patients’ 
carefully lifelong monitoring at yearly intervals is mandatory to improve the 
prognosis and outcome of AIG. New therapeutic strategies are needed to delay 
disease progression and influence the gastric atrophy, making it a reversible entity. 
Guidelines of AIG surveillance are awaited.
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